Research
Telehealth GLP-1 prescribing: real-world evidence
Real-world telehealth GLP-1 prescribing has expanded rapidly, but rigorous outcome data specific to telehealth-delivered (and especially compounded) c
Real-world telehealth GLP-1 prescribing has expanded rapidly, but rigorous outcome data specific to telehealth-delivered (and especially compounded) care is limited. Most published efficacy evidence comes from the manufacturer trials of approved products, not from telehealth cohorts using compounded drugs.
What the trials establish
Telehealth widened access to GLP-1 therapy, and observational reports describe real weight loss in these programs. But observational telehealth data carries the usual caveats: variable adherence, loss to follow-up, self-selected populations, and inconsistent outcome measurement.
For compounded products delivered by telehealth specifically, the evidence gap is larger still: the efficacy and safety data belong to the approved products studied in RCTs, and do not automatically transfer to a compounded formulation at a non-standard dose.
The reasonable stance is that telehealth is an access and delivery model, and its real-world outcomes — particularly for compounded microdoses — remain under-characterized relative to the trial evidence for approved drugs.
| Trial | Population | N | Result | Citation | Identifiers |
|---|---|---|---|---|---|
| STEP 1 | Adults with overweight/obesity, without diabetes | 1,961 | Mean weight change about -14.9% vs -2.4% placebo | Wilding JPH, et al. N Engl J Med 2021;384:989-1002 | NCT03548935 · PMID 33567185 · DOI |
Identifiers verified against ClinicalTrials.gov and PubMed. Machine-readable dataset: studies.json · studies.csv.
What remains unknown
Across this topic, the recurring gap is the same: the randomized evidence describes approved products at studied doses, while compounded and deliberately sub-therapeutic 'microdose' use sits outside it. This page marks that boundary rather than blurring it.
What the evidence shows
- The cited trials carry verified NCT, PMID, and DOI identifiers and studied approved products at labeled doses.
- Findings here reflect those trials' actual results and populations.
What the evidence does not show
- That a compounded or microdose version reproduces these results — it has not been studied.
- That approved-product evidence transfers automatically to compounded formulations.
Frequently asked questions
Is telehealth GLP-1 as effective as trials?
Trial evidence is for approved products; telehealth real-world data, especially for compounded drugs, is limited.
Does compounded telehealth inherit the trial data?
No — approved-product evidence doesn't transfer to compounded formulations.
Related: evidence database · research hub. Compounded medications are not FDA approved.
Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.